Core Viewpoint - The stock of Jimin Health Management Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from August 13 to August 15, 2025 [1][2]. Group 1: Stock Trading Abnormality - The stock price fluctuation is classified as an abnormal trading situation according to the Shanghai Stock Exchange trading rules [1]. - The company conducted a self-examination and confirmed that there were no significant changes in its main business or external operating environment, and no undisclosed major matters exist [1][2]. Group 2: Confirmation from Major Stakeholders - Written confirmation from the controlling shareholder and actual controller indicates that, apart from disclosed matters, there are no significant asset restructurings, share issuances, major transactions, business reorganizations, or other major events related to the company [2]. - The board of directors verified that there were no media reports or market rumors that could significantly impact the company's stock price during the abnormal trading period [2]. Group 3: Financial Performance - The company is expected to report a loss of 46 million yuan for the first half of 2025, compared to the same period last year, as disclosed in the half-year performance warning announcement [3]. - The current static price-to-earnings ratio is reported as a loss, while the price-to-book ratio stands at 2.91 [2]. Group 4: Board of Directors' Statement - The board of directors confirmed that there are no undisclosed matters or related plans that should be disclosed according to the Shanghai Stock Exchange listing rules [4].

Core Viewpoint - Jimin Health announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days from August 13 to August 15, 2025 [1] Summary by Relevant Sections - Stock Trading Activity - The stock price of Jimin Health showed a significant increase, with a cumulative rise exceeding 20% over three trading days [1] - Company Disclosure - The company conducted a self-examination and consulted with its controlling shareholder and actual controller, confirming that there are no undisclosed significant matters as of the date of the announcement [1]

关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025年 8 月 15 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权,为公司实际控 制人。 本家族全体成员于 2025 年 8 月 15 日收到你公司发来的《关于济 ...

●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 一、股票交易异常波动的具体情况 证券代码：603222 证券简称：济民健康 公告编号：2025-037 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●公司股票交易于2025年8月13日、8月14日、8月15日连续三个交易日内收盘 价格涨幅偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易 异常波动情形。 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 13 日、 8 月 14 日、8 月 15 日连续三个交易日内收盘价格涨幅偏离值累计达到 20%，根据 《上海证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如 ...

Group 1 - The medical device sector has regained momentum, with the medical device ETF (562600) rising by 1.08%, and key holdings like Sainuo Medical increasing by 13.72% [1] - The medical device sector outperformed the pharmaceutical and biological sector, with a growth rate of 14.27%, ranking second among six sub-industries, and surpassing the pharmaceutical sector and the CSI 300 index by 1.38 and 10.74 percentage points respectively [1] - Analysts believe the medical device industry is poised for multi-dimensional development through technological platformization, AI diagnostics expansion, and consumer healthcare advancements, indicating a shift from scale expansion to higher-level development [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All Share Medical Device Index [2] - The index comprises 100 representative listed companies in core medical fields, with the medical device sector accounting for 89.34% of the index, highlighting its concentrated structure and ability to capture industry growth [2]

证券之星消息，8月15日医疗器械板块较上一交易日上涨1.42%，赛诺医疗领涨。当日上证指数报收于 3696.77，上涨0.83%。深证成指报收于11634.67，上涨1.6%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688108 | 赛诺医疗 | 34.57 | 13.72% | 71.56万 | 23.31亿 | | 603222 | 济民健康 | 8.91 | 10.00% | 101.34万 | 8.73亿 | | 002551 | 尚荣医疗 | 4.87 | 9.93% | 51.16万 | 2.46亿 | | 688755 | 汉邦科技 | 49.43 | 7.67% | - 3.57万 | 1.74亿 | | 300246 | 宝莱特 | 10.14 | 6.85% | 37.98万 | 3.88 Z | | 300942 | 易瑞生物 | 13.08 | 6.43% | 17.46万 | 2.25亿 | | 300677 | 英科医疗 | 37 ...

Group 1 - The core viewpoint of the articles highlights a positive trend in the medical device sector, with major stocks experiencing significant gains, indicating a recovery in the market [1] - The medical device index ETF (159898) showed a morning rebound with a rise of 1.03%, attracting over 15 million yuan in net subscriptions, reflecting investor confidence [2] - Future growth in the medical device industry is expected to be driven by technological advancements, AI diagnostics, and the expansion of consumer healthcare, transitioning to a higher development stage [2] Group 2 - Financial institutions like Caixin Securities maintain a "leading the market" rating for the medical device sector, anticipating high-quality development and long-term investment opportunities [2] - The impact of centralized procurement in high-cost areas is gradually diminishing, with some products benefiting from renewed contracts, suggesting a potential for volume and price increases in the coming years [2] - The medical device index ETF (159898) has seen a cumulative net value increase of 22.82% over the past year, outperforming its benchmark by 5.99%, ranking first among similar index ETFs [2][3]

Core Viewpoint - Jimin Health has experienced a significant stock price increase of 10.00%, achieving a price of 8.91 yuan and a total market capitalization of 4.679 billion yuan, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Strategic Collaborations - The company has entered into a strategic partnership with Dabo Bio in the field of cell gene therapy, focusing on the development of oncolytic virus drugs, which aligns with the biotechnology sector within the healthcare industry [1] - Jimin Health is participating in an AI entrepreneurship development fund, integrating AI with medical technology, thus tapping into the emerging trend of AI and healthcare convergence [1] Group 2: Market Confidence Initiatives - The company has announced a share repurchase plan worth 100-200 million yuan, aimed at strengthening market confidence and supporting the buyback concept [1] Group 3: Business Segments - Jimin Health is primarily involved in several key sectors including biotechnology, artificial intelligence, medical devices, medical services, and share buybacks, reflecting a diversified approach to growth and investment opportunities [1]

济民健康(603222)今日涨停，全天换手率17.99%，成交额7.42亿元，振幅11.88%。龙虎榜数据显示，营 业部席位合计净买入465.46万元。 上交所公开信息显示，当日该股因日涨幅偏离值达10.51%上榜，营业部席位合计净买入465.46万元。 融资融券数据显示，该股最新（8月13日）两融余额为1.62亿元，其中，融资余额为1.62亿元，融券余额 为5.81万元。近5日融资余额合计增加1299.80万元，增幅为8.74%。融券余额合计增加5.68万元，增幅 4156.52%。 4月29日公司发布的一季报数据显示，一季度公司共实现营业收入1.81亿元，同比下降22.49%，实现净 利润-1363.65万元。 7月12日公司发布上半年业绩预告，预计实现净利润-5500.00万元至-4600.00万元，同比变动区间 为-316.15%~-280.78%。（数据宝） 济民健康8月14日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 东方财富证券股份有限公司上海东方路证券营 ...

证券之星消息，8月14日医疗器械板块较上一交易日下跌2.16%，利德曼领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300289 | 利德曼 | 10.06 | -11.21% | 106.05万 | | 10.85 Z | | 300981 | 中红医疗 | 16.00 | -9.91% | 26.13万 | | 4.31亿 | | 688677 | 海泰新光 | 45.30 | -7.93% | 4.91万 | | 2.28亿 | | 301235 | や康浩浄 | 29.72 | -7.90% | 15.14万 | | 4.42亿 | | 832278 | 鹿得医疗 | 11.23 | -7.88% | 9.33万 | | 1.07亿 | | 688212 | 澳华内镜 | 49.14 | -7.79% | 4.70万 | | 2.34亿 ...